Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume 35, Issue 7, Pages 1845-1852
Publisher
Wiley
Online
2014-12-30
DOI
10.1111/liv.12774
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
- (2015) Eric Lawitz et al. HEPATOLOGY
- Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease
- (2014) Benjamin Maasoumy et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
- (2014) Mark S. Sulkowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global epidemiology and genotype distribution of the hepatitis C virus infection
- (2014) Erin Gower et al. JOURNAL OF HEPATOLOGY
- Restoration of HCV-specific CD8+ T cell function by interferon-free therapy
- (2014) Bianca Martin et al. JOURNAL OF HEPATOLOGY
- Strategies to manage hepatitis C virus (HCV) disease burden
- (2014) H. Wedemeyer et al. JOURNAL OF VIRAL HEPATITIS
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents
- (2013) Jens M. Kittner et al. DIGESTIVE AND LIVER DISEASE
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
- (2013) Christophe Hézode et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
- (2013) Benjamin Maasoumy et al. PLoS One
- Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy
- (2012) Cheng-Yuan Peng et al. JOURNAL OF HEPATOLOGY
- Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: A prospective study
- (2011) Marie Angèle Robic et al. JOURNAL OF HEPATOLOGY
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
- (2011) Markus Cornberg et al. LIVER INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More